AMENDMENT 3 TO LICENSE AGREEMENTLicense Agreement • March 26th, 2009 • Jazz Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment 3 to License Agreement (the “Amendment”) is made and entered into as of the 19 day of December, 2008 (“Execution Date”), by and between SOLVAY PHARMACEUTICALS, INC., a Georgia corporation having its principal office at 901 Sawyer Road, Marietta, Georgia 30062 (“Solvay”) and JPI COMMERCIAL, LLC, a Delaware limited liability corporation and wholly-owned subsidiary of Jazz Pharmaceuticals, Inc., a Delaware corporation (“Jazz Pharmaceuticals”), having its principal offices at 3180 Porter Drive, Palo Alto, California 94304 (“JPI”). Solvay and JPI are referred to herein on occasion separately as a “Party” or together as the “Parties”. Capitalized terms used herein shall have their respective meanings set forth in the License Agreement, unless otherwise defined herein.
AMENDMENT 4 TO LICENSE AGREEMENTLicense Agreement • March 26th, 2009 • Jazz Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment 4 to License Agreement (the “Amendment”) is made and entered into as of the 5th day of February, 2009 (“Execution Date”), by and between SOLVAY PHARMACEUTICALS, INC., a Georgia corporation having its principal office at 901 Sawyer Road, Marietta, Georgia 30062 (“Solvay”) and JPI COMMERCIAL, LLC, a Delaware limited liability corporation and wholly-owned subsidiary of Jazz Pharmaceuticals, Inc., a Delaware corporation (“Jazz Pharmaceuticals”), having its principal offices at 3180 Porter Drive, Palo Alto, California 94304 (“JPI”). Solvay and JPI are referred to herein on occasion separately as a “Party” or together as the “Parties”. Capitalized terms used herein shall have their respective meanings set forth in the License Agreement, unless otherwise defined herein.
AMENDMENT TO SETTLEMENT AGREEMENTSettlement Agreement • March 26th, 2009 • Jazz Pharmaceuticals Inc • Pharmaceutical preparations
WHEREAS, on or about July 11, 2007, a settlement agreement (the “Settlement Agreement”) was entered into among the United States of America, acting through its Department of Justice and the United States Attorney’s Office for the Eastern District of New York, the Office of Inspector General of the Department of Health and Human Services (“HHS-OIG”), the United States Office of Personnel Management (“OPM”), and the United States Department of Defense TRICARE Management Activity (“TMA”) (collectively the “United States”); Jazz Pharmaceuticals, Inc. (“JPI”) and Orphan Medical, Inc. (which merged in 2008 into Orphan Medical, LLC) (“Orphan”) (JPI and Orphan are collectively referred to as “Defendants”); and Shelley Lauterbach (the “Relator”); through their authorized representatives (collectively, all of the above will be referred to as “the Parties”);
